Insights from 2023 ESMO Asia Annual Meeting
LARA Trial: Preliminary Efficacy of Pembro + Lenvatinib in Recurrent Clear Cell Gynecological Cancer
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Natalie Ngoi
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Natalie Ngoi
Comments 0
Login to view comments.
Click here to Login
